WO2000037093A1 - Inhibiteur de resorption osseuse - Google Patents
Inhibiteur de resorption osseuse Download PDFInfo
- Publication number
- WO2000037093A1 WO2000037093A1 PCT/JP1999/007152 JP9907152W WO0037093A1 WO 2000037093 A1 WO2000037093 A1 WO 2000037093A1 JP 9907152 W JP9907152 W JP 9907152W WO 0037093 A1 WO0037093 A1 WO 0037093A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- bone resorption
- activating protein
- protein factor
- leukocyte
- bone
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to a bone resorption inhibitor characterized by containing a leukocyte activating protein factor or a substance derived from a leukocyte activating protein factor as an active ingredient. Furthermore, the present invention relates to a method for screening a bone resorption inhibitor using a leukocyte activating protein factor or a substance derived from a leukocyte activating protein factor.
- LECT 2 Leukocyte activating protein factor
- LECT2 Leukocyte activating protein factor
- JP-A-8-140683 Cloning has been performed on human and human LECT2, and their nucleotide sequences have been determined (S. Yamago eeta 1., Immunol. Lett. 5Z, 9-13, 1996, S. Yamago eeta 1, Biochem. Biophys. Acta, 1396, 105—113, 1998). It has been clarified that the mRNA of human LECT2 encodes 151 amino acids including an amino acid sequence of 18 which is considered to be a signal peptide.
- LECT2 The amino acid sequences of mouse and human LECT2 have a high homology with the chicken mim-1 gene product, and although the function of this mim-1 gene product is unknown, it is found in the granules of bone marrow promyelocytic cells. It is known that myb, an oncogene, is involved in the regulation of expression.c The effect of LECT2, which was discovered as a chemotactic factor, was measured by activating neutrophils. It is suggested that it can be used for the treatment, diagnosis, and prognosis of tumor immunity because it induces an enhanced destructive reaction and promotes the secretion of inleucine leukins, and enhances innate immunity. LECT 2 is only known to be associated with neutrophil activation, and has no known effect on bone (Protein nucleic acid enzyme (7), 1086, 1997).
- chondromodulin 2 a protein with a molecular weight of about 16 KDa, purified from fetal cartilage (Y. Hiraki et al., J. Biol. Chem. 271, 22657-22662). , 1996). Chondromodulin 2 has been shown to promote the proliferation and differentiation of chondrocytes (Japanese Patent Laid-Open Publication No. 5-255398), and also has an effect of promoting osteoclast formation and activating osteoclasts. (Japanese Patent Laid-Open Publication No. Hei 8-27020). Recently, a homology search revealed that LECT2 and chondromodulin 2 were identical.
- Osteoclasts are multinucleated giant cells that exist in bone tissue for the purpose of bone resorption and play an important role in bone remodeling.
- Osteoclast precursor cells are cells derived from hematopoietic stem cells, which are transported to the bone surface via the bloodstream and differentiate into osteoclasts.
- Osteoblasts differentiate from progenitor cells belonging to stromal cells such as undifferentiated mesenchymal cells, fibroblasts, and stromal cells, and are derived from progenitor cells that have a completely different cell lineage from osteoclasts. are doing. Bone is constantly undergoing bone formation and resorption, and undergoes bone remodeling.
- bone remodeling involves the resorption of bone by osteoclasts, followed by osteoblasts forming bone in the resorbed area and maintaining a balance. If the balance becomes abnormal due to various reasons with aging, bone mass decreases, and if this condition continues for a long period of time, the bone tissue becomes brittle, and various bone diseases such as osteoporosis, fractures, and back pain may occur. become.
- Estrogens, calcitonin, bisphosphonates and the like are known as drugs having a bone resorption inhibitory action, all of which have been reported to have side effects. Therefore, a drug that can effectively suppress bone resorption by osteoclasts and that is highly safe has been desired. Disclosure of the invention
- An object of the present invention is to provide a novel bone resorption inhibitor.
- LECT2 or a substance derived from LECT2 has a bone resorption inhibiting action. Is the most important feature. By utilizing this knowledge, they have realized to provide a novel bone resorption inhibitor.
- the present inventors have conducted intensive studies and, as a result, have found, as an effect of LECT2 on bone, an effect of suppressing bone resorption, particularly an effect of suppressing bone resorption on osteoclasts, and completed the present invention.
- the present invention relates to a bone resorption inhibitor comprising LECT2 or a substance derived from LECT2 in an amount effective for suppressing bone resorption.
- LECT 2 or a substance derived from LECT 2 having the amino acid sequence of amino acids 1 to 15 or 19 to 151 in SEQ ID NO: 1 in the sequence listing is used for inhibiting bone absorption.
- a bone resorption inhibitor comprising an effective amount.
- the bone resorption inhibitor of the present invention may be a bone resorption inhibitor in which leukocyte activating protein factor or a substance derived from leukocyte activating protein factor suppresses bone resorption by osteoclasts.
- the present invention also provides an in vitro test for bone resorption of a bone resorption inhibitor candidate compound prepared using leukocyte activating protein factor or a substance derived from leukocyte activating protein factor as a starting material, or prepared using these as an information source.
- the present invention relates to a screening method for a bone resorption inhibitor, which comprises conducting a screening test as an index and selecting the same.
- the present invention relates to a compound which exhibits a bone resorption inhibitory effect of at least 80% at a concentration of 10 ⁇ g / ml by a pit assay, among candidate compounds selected by the above-described bone resorbing agent screening method. And a bone resorption inhibitor containing this compound as an active ingredient.
- Another embodiment of the present invention is the use of a leukocyte activating protein factor or a substance derived from a leukocyte activating protein factor in the production of a bone resorption inhibitor.
- Still another aspect of the present invention is a method for inhibiting bone resorption in an animal, which comprises administering an effective amount of a leukocyte-activating protein factor or a leukocyte-activating protein factor-derived substance in an amount effective for inhibiting bone resorption.
- Fig. 1 is a drawing showing the results of testing the activity of human LECT2 (hLECT2) to inhibit bone resorption against unfractionated bone cells using a bit assay.
- the horizontal axis shows the concentration of human LECT2, and the vertical axis shows the number of bits per ivory slice.
- Human LECT 2 exhibited about 50% of bone resorption inhibiting activity at a concentration of 1 g / m1, and almost 100% of bone resorption inhibiting activity at a concentration of 10 g / m1.
- FIG. 2 is a drawing showing the results of a test of the bone resorption inhibitory activity of human LECT 2 (hLECT 2) on purified osteoclasts, using a bit assay. Similar to the pit assay using unfractionated osteocytes, the human LEC T2 is 1 in the bit assay using purified osteoclasts. At a concentration of about 100%, the activity of inhibiting bone resorption was demonstrated.
- LECT 2 of the present invention concentrates proteins from culture supernatants of cells such as leukemia cells with CM-Sepharose, and performs DEPA-Sepharose, CM-Sepharose, hydroxyapatite by HP LC, and reverse phase chromatography. It can be purified by applying. For example, cultured leukemia cells such as SKW-3 are stimulated with PHA-1P to release the leukocyte activating factor of the present invention into the culture supernatant, and from this supernatant, using a method such as column chromatography, It can be purified. Further, LECT 2 or a substance derived from LECT 2 of the present invention may be prepared by using a genetic engineering technique (Japanese Patent Application Laid-Open No.
- Japanese Patent Application Laid-Open No. 10-146189 it may be produced by a transformant prepared using pMALTM-C or pGEX-3X as a vector.
- host cells conventionally known bacteria (such as Escherichia coli), yeast and animal cells can be used.
- animal cells include Chinese ham cells—CHO cells, monkey CVI cells, monkey COS cells, mouse fibroblasts, mouse C127 cells, mouse 3T3 cells, mouse L929 cells, and human HeLa cells. can give.
- yeast baker's yeast, Pichia yeast, and other well-established production systems are convenient for use. It is most convenient to use the yeast secretion system for the purpose of industrial production. It is.
- Culture of the present cells, purification of the protein of the present invention from the culture supernatant, production of recombinant plasmid, transformation methods, and purification from transformation can be carried out by known methods.
- LECT2 used in the present invention is not particularly limited as long as it suppresses bone resorption.
- One or more amino acids in the known LECT 2 amino acid sequence are deleted, substituted, and influential! ], Insertion or induction, and those that suppress bone resorption (Ulmer, KM, Science, _2_19, 666, 1983).
- LECT 2 derived materials also include chimeric proteins, fusion proteins, partial deletions, partial sequences and chemically modified ones.
- peptides or low-molecular-weight compounds that are discovered based on various LECT 2 protein information (primary, secondary, tertiary structure, and three-dimensional surface structure) can also be candidate compounds.
- the bone resorption inhibiting activity of LECT2 or a substance derived from LECT2 is measured, for example, as follows. ⁇ Seed osteoclasts isolated from a heron on ivory pieces and measure the number of pits formed on the next day.
- the inhibitory activity of the candidate compound on bone resorption can be measured by adding the modified compound created as described above and reducing the number of pits formed (Tak edaeta 1, Bone and Mineral 1_, 347-359 , 1992) (Kameda et al., Nihon Pharmacological Journal ⁇ 09, 75-84, 1997).
- the candidate compound of the bone resorption inhibitor is screened using the inhibition rate obtained by this measurement as an index, and for example, a compound exhibiting an inhibition rate of 80% at a concentration of 10 g / ml is selected.
- bone diseases for which the bone resorption inhibitor of the present invention can be used include osteoporosis, hypercalcemia, hyperparathyroidism, pageet's disease and the like.
- the bone resorption inhibitor of the present invention When the bone resorption inhibitor of the present invention is administered as a therapeutic agent, it is usually
- LO mg / kg preferably 0.01 to 3 mg / kg may be administered once to three times a day, depending on the compound used, age, It can be increased or decreased as appropriate depending on the symptoms.
- the bone resorption inhibitor of the present invention can be administered orally, parenterally, or topically according to the administration route, if desired.
- oral administration in consideration of the problems of digestion and degradation and intestinal absorption in the case of proteins or peptides, solid preparations such as powders, granules, capsules and tablets, or liquid preparations such as syrups and elixirs It can be.
- parenteral preparations can be prepared as injections, infusions, or mucosal preparations or external preparations in consideration of the problem of mucosal or skin absorption.
- a known carrier or the like may be used in combination to prepare an oral preparation such as a tablet, capsule, granule, powder, syrup, enteric-soluble preparation, or injection ( It is formulated into parenteral preparations such as intravenous, intramuscular, subcutaneous, and intraperitoneal), infusions, suppositories, and the like.
- compositions are prepared by adding excipients, coloring agents, stabilizing agents, binders, disintegrants, lubricants, corrigents, solubilizers, adhesives, emulsifiers, liposome preparations,
- the preparation can be carried out using known adjuvants usually used in the pharmaceutical preparation technical field such as H adjuster, suspension, coating agent, intestinal absorption enhancer, sustained release preparation and the like.
- Example 1 Example 1
- Ivory slices 20-40 mm thick were cut into 6 mm diameter disks and sterilized by sonication in 70% ethanol.
- C_ ⁇ 2 incubator completely take dividing the culture solution in Uweru
- the culture broth and 5 X 10 5 cells of unfractionated bone cells including human LE CT 2 of each concentration was added pressure, further C0 2 incubator in one at (5% C 0 2/95 % A ir), and incubated 37 ° C, 18 hours.
- osteoclasts After 18 hours, completely remove the bone cells adhering to the ivory slice using a mule policeman, stain with acidic hematoxylin solution for several minutes, and count the number of pits per ivory slice under a microscope. The bone resorption activity of osteoclasts was determined by the method.
- the horizontal axis in FIG. 1 shows the concentration of human LECT2 used in the Atsushi system, and the vertical axis shows the number of bits per ivory slice.
- Human LECT2 showed about 50% bone resorption inhibitory activity at a concentration of 1 ⁇ g / ml, and almost 100% bone resorption inhibitory activity at a concentration of 10 ⁇ g / ml.
- Example 2
- the cells were washed from the gel by washing three times with 1 PBS. Further, a 0.001% pronase E / 0.02% EDTA solution was added, the mixture was allowed to stand at room temperature for 15 minutes, and then washed again three times with 1 Oml of PBS. Finally, add 0.01% collagenase solution, leave at room temperature for 5 minutes, and wash 3 times with 1 Oml of PBS to completely remove cells other than osteoclasts from the gel. Removed. To the osteoclasts remaining on the gel, a 0.1% collagenase solution was added, and the mixture was allowed to stand at room temperature for 10 minutes to dissolve the entire cell scaffold, and a cell suspension containing only osteoclasts was recovered.
- Example 2 shows the results of a study on the bone resorption inhibitory activity of human LECT2 using this Atsey system.As with Pizoto Atsey using unfractionated bone cells, human LECT2 had a concentration of 10 ⁇ / 1111. Showed almost 100% inhibition of bone resorption.
- Example 3
- a compound consisting of the amino acid sequence of SEQ ID NOS: 19 to 151 was prepared by a known method, and 0.1 mg / g was administered to a group of 5 dd mice weighing 20 ⁇ 1 g at 0.1 mg / g via the tail vein. did. Observation was continued until 7 days after administration, and no deaths could be confirmed.
- LECT 2 was found to suppress bone resorption activity. According to the invention thus, it is possible to provide an effective treatment for hypercalcemia, osteoporosis and the like. Furthermore, a screening method for a bone resorption inhibitor for a substance derived from LECT2 was provided.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Marine Sciences & Fisheries (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP99959921A EP1142579A4 (en) | 1998-12-22 | 1999-12-20 | BONE RESORPTION INHIBITOR |
US09/868,953 US6723696B1 (en) | 1998-12-22 | 1999-12-20 | Bone resorption inhibitors |
CA002356765A CA2356765A1 (en) | 1998-12-22 | 1999-12-20 | Bone resorption inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP36372798A JP4378439B2 (ja) | 1998-12-22 | 1998-12-22 | 骨吸収抑制剤 |
JP10/363727 | 1998-12-22 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2000037093A1 true WO2000037093A1 (fr) | 2000-06-29 |
WO2000037093A8 WO2000037093A8 (fr) | 2000-11-02 |
Family
ID=18480042
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/007152 WO2000037093A1 (fr) | 1998-12-22 | 1999-12-20 | Inhibiteur de resorption osseuse |
Country Status (5)
Country | Link |
---|---|
US (1) | US6723696B1 (ja) |
EP (1) | EP1142579A4 (ja) |
JP (1) | JP4378439B2 (ja) |
CA (1) | CA2356765A1 (ja) |
WO (1) | WO2000037093A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010031361A1 (zh) * | 2008-09-22 | 2010-03-25 | 台湾东洋药品工业股份有限公司 | 抑制病理性血管发生作用的组合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0827020A (ja) * | 1994-07-19 | 1996-01-30 | Mitsubishi Chem Corp | 破骨細胞形成促進及び骨吸収剤 |
EP0723016A2 (en) * | 1994-11-28 | 1996-07-24 | Kazuo Suzuki | Activating factor of leukocytes |
JPH10146189A (ja) * | 1996-11-15 | 1998-06-02 | Mitsubishi Chem Corp | 新規な遺伝子およびそれを用いた組換えタンパク質の製造方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR0176418B1 (ko) * | 1996-03-29 | 1999-04-01 | 김은영 | 인체 조직 유래의 엠아이엠-1 상동 유전자 |
US6306608B1 (en) * | 1996-05-27 | 2001-10-23 | Medical & Biological Laboratories Co., Ltd. | Anti-human LECT2 antibody, cells producing the same, and method and kit for assaying the same |
JP3613909B2 (ja) | 1996-11-12 | 2005-01-26 | ダイキン工業株式会社 | 空調用通路付き建材 |
-
1998
- 1998-12-22 JP JP36372798A patent/JP4378439B2/ja not_active Expired - Lifetime
-
1999
- 1999-12-20 CA CA002356765A patent/CA2356765A1/en not_active Abandoned
- 1999-12-20 US US09/868,953 patent/US6723696B1/en not_active Expired - Fee Related
- 1999-12-20 EP EP99959921A patent/EP1142579A4/en not_active Withdrawn
- 1999-12-20 WO PCT/JP1999/007152 patent/WO2000037093A1/ja not_active Application Discontinuation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0827020A (ja) * | 1994-07-19 | 1996-01-30 | Mitsubishi Chem Corp | 破骨細胞形成促進及び骨吸収剤 |
EP0723016A2 (en) * | 1994-11-28 | 1996-07-24 | Kazuo Suzuki | Activating factor of leukocytes |
JPH10146189A (ja) * | 1996-11-15 | 1998-06-02 | Mitsubishi Chem Corp | 新規な遺伝子およびそれを用いた組換えタンパク質の製造方法 |
Non-Patent Citations (2)
Title |
---|
MORI ET AL: "STIMULATION OF OSTEOBLAST PROLIFERATION BY THE CARTILAGE-DERIVED GROWTH PROMOTING FACTORS CHONDROMODULIN-I AND -II", FEBS LETTERS, vol. 406, no. 3, 1997, pages 310 - 314, XP002922590 * |
See also references of EP1142579A4 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010031361A1 (zh) * | 2008-09-22 | 2010-03-25 | 台湾东洋药品工业股份有限公司 | 抑制病理性血管发生作用的组合物 |
Also Published As
Publication number | Publication date |
---|---|
WO2000037093A8 (fr) | 2000-11-02 |
JP4378439B2 (ja) | 2009-12-09 |
JP2000186045A (ja) | 2000-07-04 |
US6723696B1 (en) | 2004-04-20 |
CA2356765A1 (en) | 2000-06-29 |
EP1142579A4 (en) | 2004-12-15 |
EP1142579A2 (en) | 2001-10-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10654905B2 (en) | Method of treating graft versus host disease with an interleukin-2 mutein | |
EP1286684B1 (en) | use of cxcr4 antagonists for treating autoimmune diseases and cancer | |
KR101997757B1 (ko) | 악액질 예방 또는 치료용 조성물 | |
EP1843789B1 (en) | Compositions and methods for treating fibrotic disorders | |
US7435718B2 (en) | CXCR4 antagonist treatment of hematopoietic cells | |
EP0833912B1 (en) | Novel tgf-beta like cytokine | |
AU2001258110A1 (en) | Cxcr4 antagonist treatment of hematopoietic cells | |
EA005581B1 (ru) | ПОЛИПЕПТИДЫ ЦИТОКИНА Zcyto10 ЧЕЛОВЕКА И МЫШИ, КОДИРУЮЩИЕ ИХ ПОЛИНУКЛЕОТИДЫ И АНТИТЕЛА К УКАЗАННЫМ ПОЛИПЕПТИДАМ | |
Lomedico et al. | Molecular biology of interleukin-1 | |
Caputo et al. | Structure and differential mechanisms of regulation of expression of a serine esterase gene in activated human T lymphocytes. | |
WO2000037093A1 (fr) | Inhibiteur de resorption osseuse | |
CN108295242B (zh) | 用于预防和/或治疗银屑病药物组合物、cd317胞外段蛋白的应用 | |
EA005973B1 (ru) | Применение sarp-1 для лечения и/или предупреждения склеродермии | |
KR100313736B1 (ko) | 사람유래종양세포증식저해인자 | |
US6846647B1 (en) | Polypeptides suppressing smooth muscle cell proliferation, the encoding cDNA, and related methods | |
JP3106191B1 (ja) | Fgf−5の生理的機能制御ペプチド及び該ペプチドを含有する医薬組成物 | |
JP2002533402A (ja) | 癌を処置するためおよび樹状細胞の走化性を媒介するための方法 | |
KR100885545B1 (ko) | Rank 저해 활성을 갖는 폴리펩티드, 그를 포함하는약학적 조성물, 그를 이용한 개체의 파골세포 분화를억제하는 방법 및 파골세포의 분화 및 활성화로 인하여야기되는 질병을 치료 또는 예방하는 방법, 그를 코딩하는핵산, 상기 핵산을 포함하는 벡터 및 숙주세포 | |
JP7503794B2 (ja) | インターロイキン-2のスーパーアンタゴニスト、パーシャルアゴニスト及びアンタゴニスト | |
AU711368B2 (en) | Novel TGF-beta like cytokine | |
WO2002072134A1 (fr) | Remedes pour l'arthrite deformante et pour l'arthrite rhumatoide | |
WO2001082948A2 (en) | Uses of tgap7 for the modulation of leucocyte activation | |
Ha et al. | Advances in Biomedical Research | |
CA2408319A1 (en) | Cxcr4 antagonist treatment of hematopoietic cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: C1 Designated state(s): CA US |
|
AL | Designated countries for regional patents |
Kind code of ref document: C1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
WR | Later publication of a revised version of an international search report | ||
ENP | Entry into the national phase |
Ref document number: 2356765 Country of ref document: CA Ref country code: CA Ref document number: 2356765 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1999959921 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 09868953 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 1999959921 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1999959921 Country of ref document: EP |